Pérez-Aguilar F, Berenguer M, Ramírez-Palanca J J, Payà A, Vera-Sempere F J, Sánchez-Cuenca J M, Berenguer J
Servicio de Medicina Digestiva, Hospital La Fe, Valencia.
Med Clin (Barc). 1996 Mar 30;106(12):460-2.
Droxicam in a nonsteroid antiinflammatory from the oxicam family which acts as a pro-drug, being transformed into pyroxicam after being hydrolized in the stomach and has induced several cases of cholestatic or mixed hepatitis. A clinical observation in which droxicam provoked initial cholestatic hepatitis which later developed into chronic autoimmune hepatitis is presented. It has been postulated that, after causing cholestatic hepatitis by hypersensitivity and within the context of a previous autoimmune entity such as vitiligo, this drug triggered a silent autoimmune liver disease which was demonstrated clinical, analytical and histopathological manifestations 18 months later and required permanent immunosuppressive treatment.
屈昔康是昔康类非甾体抗炎药,作为前体药物,在胃中水解后转化为吡罗昔康,已引发多例胆汁淤积性或混合性肝炎。本文介绍了一项临床观察,屈昔康引发了初始胆汁淤积性肝炎,随后发展为慢性自身免疫性肝炎。据推测,该药物通过超敏反应导致胆汁淤积性肝炎后,在先前存在自身免疫性疾病(如白癜风)的情况下,引发了一种隐匿性自身免疫性肝病,18个月后出现临床、分析和组织病理学表现,需要长期免疫抑制治疗。